# Bio-Techne account plan

> Bio-Techne makes life science reagents, instruments and diagnostics; FY2026 net sales $1,215.0 million, about 3,000 staff, being acquired by Merck KGaA.

## At a glance

Bio-Techne, headquartered in Minneapolis and listed on NASDAQ (TECH), develops, manufactures and sells life science reagents, instruments and services for the research, diagnostics and bioprocessing markets. Its customers are academic and industry researchers (chiefly pharma, biotech and CROs), diagnostic developers and cell- and gene-therapy developers. In the fiscal year ended June 30, 2026 it reported net sales of $1,215.0 million, flat on FY2025, and GAAP net earnings of $181.9 million; it had about 3,000 employees, about 2,200 of them in the U.S. Revenue is consumables-heavy ($985.1 million in FY2026), and most products are manufactured in-house in North America, the U.K., Canada, Switzerland and China. On June 25, 2026 it agreed to be acquired by Merck KGaA, Darmstadt, Germany, for $73.00 per share in cash; shareholders approved the deal on September 23, 2026 and closing is expected by late 2026 or early 2027.

## Business units

- **Protein Sciences** (about 72% of FY2026 net sales ($874.6 million)): Reagent Solutions (proteins, antibodies, small molecules and cGMP reagents for cell and gene therapy under the R&D Systems, Tocris and Novus Biologicals brands) and Analytical Solutions (ProteinSimple automated protein analysis instruments and immunoassays). FY2026 sales rose 1% with segment operating income of $359.4 million, and Q1 FY2027 sales reached $219.7 million, up 9%. Led by William Geist, President, Protein Sciences.
- **Diagnostics and Spatial Biology** (about 28% of FY2026 net sales ($336.4 million)): Spatial Biology (RNAscope in-situ hybridization assays and the Lunaphore COMET instrument) and Bio-Techne Diagnostic (regulated calibrators and controls sold mostly OEM to instrument makers, plus Asuragen molecular diagnostics). FY2026 sales fell 3% after the Exosome Diagnostics divestiture, while segment operating income rose from $21.3 million to $37.7 million. Led by Steve Crouse, President since March 1, 2026.

## Strategic priorities

- **Closing the Merck KGaA merger**: Merck KGaA agreed to buy Bio-Techne at $73.00 per share, an enterprise value of about US$11.3 billion; shareholders approved it on September 23, 2026 and closing is expected by late 2026 or early 2027. Merck KGaA targets about EUR 140 million of annual cost synergies, fully realized by year 3 after closing.
- **Four growth verticals**: Cell therapy, proteomic analysis, spatial biology and precision diagnostics were 47% of total revenue in Q2 FY2026, up from 32% in fiscal 2020, and address a $27 billion market growing at a mid-teens rate, all pulling through the core reagents.
- **Brand simplification**: In April 2026 the company moved from 10 brands to 3 (R&D Systems, Bio-Techne Spatial Biology, Bio-Techne Diagnostics), and a Q4 FY2026 restructuring for a streamlined brand architecture and realigned functions continues into fiscal 2027.
- **Margin expansion**: The CEO expects gross margin to stay north of 70% and, under normalized growth, margins to improve by at least a hundred basis points annually, helped by productivity, AI and the exit from lower-margin businesses.
- **AI-designed proteins and data**: Bio-Techne uses AI models trained on five decades of proprietary data to design novel, patentable proteins, deploys AI across the organisation for productivity and customer engagement, and labels data so customers can use it with large language models.
- **Cell therapy and GMP capacity**: GMP reagents grew nearly 50% in Q3 FY2026 excluding two Fast Track customers; the cell therapy base counts 700+ customers and 85 programmes in clinical trials, and the CEO wants at least 20% trailing-12-month growth in cell therapy.

## Latest results

In Q1 FY2027 (quarter to September 30, 2026) net sales were $299.7 million, up 5%, with organic growth of 7% and a 2% headwind from the divested Exosome Diagnostics business. Protein Sciences grew 9% to $219.7 million, while Diagnostics and Spatial Biology grew 1% to $80.2 million and its operating margin fell to 7.4% from 11.2%. GAAP net earnings fell to $28.3 million (diluted EPS $0.18 vs $0.24) as acquisition-related expenses rose to $17.9 million; adjusted EPS was $0.44 vs $0.42 and adjusted gross margin 69.3% vs 70.2%. Operating cash flow was $73.1 million and cash $350.0 million. No numeric guidance is given in the filings; on the Q3 FY2026 call the CFO said the company would be disappointed without at least mid-single-digit growth in fiscal 2027.

## Investments and deals

- **Wilson Wolf buyout**: Bio-Techne owns 19.9% of Wilson Wolf (G-Rex cell culture devices) and must buy the remaining 80.1% by December 31, 2027 for about $1 billion plus potential contingent consideration, forecast between fiscal 2027 and fiscal 2028.
- **Capacity capex**: Capital additions were $28.9 million in FY2026; about $28 million more is expected in fiscal 2027 for capacity to meet expected sales growth.
- **Exosome Diagnostics divestiture**: Exosome Diagnostics was sold for MDxHealth shares received in September 2025, after a cumulative impairment of $83.1 million; a $5.9 million loss on the MDxHealth investment was booked in FY2026.
- **Restructuring programmes**: The FY2025 margin-recovery and manufacturing-footprint programme was completed by the end of fiscal 2026; restructuring and related costs totalled $21.1 million in FY2026, and a new Q4 programme runs through fiscal 2027.
- **New products and earlier deals**: Over 1,900 new products were launched in FY2026, including the Leo high-throughput western blot and CE-IVD marking for Ella; earlier moves include Lunaphore, acquired for $169.7 million, and a $15.0 million investment in Spear Bio in fiscal 2025.

## Challenges and risks

- **Merger disruption**: The 10-K flags substantial transaction costs, difficulty retaining personnel and senior management, and strain on relationships with customers, suppliers and distributors while the deal is pending; buybacks are prohibited without Merck KGaA's consent.
- **Mix and pricing pressure**: Adjusted gross margin slipped to 69.6% in FY2026 from 70.4%, and Protein Sciences sales were impacted by unfavorable product mix and pricing pressures.
- **Uneven end markets**: Emerging biotech fell high single digits in Q3 FY2026 as funding moved toward late-stage programmes, and the CEO called academia still a frail market; U.S. sales fell to $635.4 million in FY2026 from $683.2 million.
- **Customer concentration in cell therapy**: Two cell therapy customers with FDA Fast Track designation cut GMP reagent sales by 50% in Q2 FY2026 and created a 400 basis point headwind in Q3 FY2026.
- **Diagnostics order timing**: Bulk diagnostic lots ship on customer schedules, so revenue can swing from quarter to quarter, and the segment's operating margin fell to 7.4% in Q1 FY2027.

## What leadership says

> "As part of Merck KGaA, Darmstadt, Germany, we will have greater scale and expanded capabilities to accelerate innovation and deepen our impact." — Kim Kelderman, President and CEO, Joint press release on the Merck KGaA acquisition, June 25, 2026

> "We should be able under normalized growth conditions to improve our margins by at least a hundred basis points annually." — Kim Kelderman, President and CEO, TD Cowen Insights podcast, recorded March 3, 2026

> "we'd be disappointed if we didn't do at least mid-single-digit growth" — James Hippel, CFO, Q3 fiscal 2026 earnings call, May 6, 2026, on fiscal 2027

> "It's still a frail market. It's certainly not going to be a V-shaped recovery" — Kim Kelderman, President and CEO, Q3 fiscal 2026 earnings call, May 6, 2026, on academia


## Where a supplier can help

- **Integration support ahead of the Merck KGaA close**: Tied to the pending merger and its EUR 140 million cost-synergy target: systems, data migration and change-management providers can help align processes, while vendor decisions may move toward the acquirer's structures.
- **Brand consolidation execution**: Tied to the move from 10 brands to 3 and the restructuring running through fiscal 2027: digital catalogue, web, product-data and marketing-operations suppliers can help make products easier to find on digital and AI-driven platforms.
- **Manufacturing capacity and GMP quality**: Tied to the fiscal 2027 capacity capex and cell therapy growth goals: equipment, automation, quality and validation suppliers fit the GMP reagent build-out.
- **Productivity and AI tooling**: Tied to the margin-expansion priority and AI use across the organisation: automation, analytics and AI platform providers can support productivity gains.
- **Talent retention during the transaction**: Tied to the merger challenge of retaining personnel: HR, engagement and recruiting providers can help keep critical scientific and commercial staff.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Bio-Techne Annual Report on Form 10-K, fiscal year ended June 30, 2026](https://www.sec.gov/Archives/edgar/data/842023/000110465926100322/tech-20260630x10k.htm)

Annual report · 2026-08-24

- Bio-Techne (Minneapolis, NASDAQ: TECH, founded 1976 as Research and Diagnostic Systems) makes life science reagents, instruments and services for research, diagnostics and bioprocessing; about 3,000 employees at June 30, 2026 (about 2,200 in the U.S., about 800 outside).
- **Being acquired**: on June 25, 2026 it signed a merger agreement with Merck KGaA, Darmstadt, Germany, at $73.00 per share in cash; closing expected by late 2026 or early 2027, subject to regulatory approvals. Termination fees: about $230.5 million payable by Bio-Techne, about $576.1 million by Merck KGaA in specified cases.
- FY2026 net sales $1,215.0 million, flat on FY2025 ($1,219.6 million); organic growth 0%, FX +2%, a business held for sale -2%. Consumables $985.1 million, instruments $110.6 million, services $94.3 million, royalties $25.0 million.
- Two segments: **Protein Sciences** (about 72% of FY2026 net sales, $874.6 million, segment operating income $359.4 million) and **Diagnostics and Spatial Biology** (about 28%, $336.4 million, segment operating income $37.7 million).
- Profitability: GAAP gross margin 65.8%, adjusted gross margin 69.6% (70.4% in FY2025), hurt by unfavorable product mix and pricing pressure; GAAP net earnings $181.9 million (diluted EPS $1.16), adjusted EPS $1.93 vs $1.92.
- Geography: United States $635.4 million (down from $683.2 million), EMEA excl. UK $294.2 million, Greater China $104.1 million, APAC excl. China $85.8 million, UK $56.3 million.
- Portfolio moves: Exosome Diagnostics divested (MDxHealth shares received in September 2025); Wilson Wolf (G-Rex cell-culture devices) 19.9% owned, the remaining 80.1% to be bought by December 31, 2027 for about $1 billion plus potential contingent consideration; a Q4 restructuring for a streamlined brand architecture continues into fiscal 2027.
- Strategy pillars: grow and leverage the core, capitalize on high-potential markets, expansion through innovation and acquisition, best-in-class customer experience, EPIC culture; over 1,900 new products launched in FY2026.
- Leadership: Kim Kelderman (President and CEO), James Hippel (CFO), William Geist (President, Protein Sciences), Steve Crouse (President, Diagnostics and Spatial Biology since March 1, 2026).

### [Bio-Techne Quarterly Report on Form 10-Q, first quarter of fiscal 2027 (quarter ended September 30, 2026)](https://www.sec.gov/Archives/edgar/data/842023/000110465926123907/tech-20260930x10q.htm)

Interim report · 2026-11-06

- Q1 FY2027 (quarter to September 30, 2026) net sales $299.7 million, up 5%; organic growth 7%, with a held-for-sale business a 2% headwind and FX immaterial.
- Protein Sciences sales $219.7 million, up 9% (organic 9%), operating margin 37.9% (38.4% a year earlier); Diagnostics and Spatial Biology $80.2 million, up 1% (organic 1%), operating margin 7.4% (11.2%).
- Revenue by type: consumables $237.3 million, instruments $25.5 million, services $22.5 million, royalties $14.5 million (from $5.6 million).
- By geography: United States $152.7 million (down from $155.2 million), EMEA excl. UK $73.9 million (up from $65.1 million), Greater China $28.9 million (up from $24.8 million), APAC excl. China $22.5 million.
- GAAP net earnings fell to $28.3 million (diluted EPS $0.18 vs $0.24) as acquisition-related expenses rose to $17.9 million; adjusted EPS $0.44 vs $0.42. Adjusted gross margin 69.3% vs 70.2%.
- Merger with Merck KGaA, Darmstadt, Germany: shareholders approved it on September 23, 2026; closing expected by late 2026 or early 2027. Share buybacks are prohibited without Merck KGaA's consent while the agreement is in effect.
- Cash $350.0 million, with $800.0 million available on the credit line; operating cash flow $73.1 million; remaining fiscal 2027 capex about $28 million, for capacity to meet expected sales growth.
- Wilson Wolf: the payment of about $1 billion for the remaining 80.1% is still forecast between fiscal 2027 and fiscal 2028.

### [Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne (joint press release, Form 8-K Exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/842023/000199937126013429/ex99-1.htm)

Report · 2026-06-25

- Merck KGaA, Darmstadt, Germany, agreed on June 25, 2026 to acquire Bio-Techne for US$73 per share in cash, an enterprise value of about US$11.3 billion (EUR 9.9 billion), a 36% premium to the one-month volume-weighted average price.
- Rationale: expand in multi-omics, spatial biology, precision diagnostics, cell and gene therapy and advanced research tools, and add capabilities across Merck KGaA's Discovery Solutions, Advanced Solutions and Process Solutions offerings.
- Merck KGaA expects about EUR 140 million of annual cost synergies, fully realized by year 3 after closing; the deal is expected to be immediately accretive to EBITDA pre margin and EPS pre accretive by year 3.
- What Bio-Techne brings: recombinant proteins (cytokines, growth factors, antibodies, immunoassay kits), ProteinSimple automated protein analysis instruments, RNAscope in situ hybridization, and a cell therapy position including the Wilson Wolf G-Rex stake.
- Bio-Techne at signing: more than 3,000 employees (about 2,300 in the U.S.), 34 global locations, 15 manufacturing facilities in the U.S., Canada, the UK, Switzerland and China, net sales of more than US$1.2 billion in fiscal 2025.
- Funding from cash and new debt; closing expected by late 2026 or early 2027, subject to regulatory and Bio-Techne shareholder approval.
- Voices: Kai Beckmann (Merck KGaA Group CEO), Jean-Charles Wirth (CEO Life Science), Kim Kelderman (Bio-Techne CEO) and Robert V. Baumgartner (Bio-Techne Chairman).

### [Bio-Techne at 50: Five Decades of Platform Evolution (TD Cowen Insights podcast)](https://www.tdsecurities.com/ca/en/tdc-health-care-conference-2026-bio-techne)

Podcast · Kim Kelderman, President and Chief Executive Officer · 2026-03-30

- Recorded March 3, 2026 at the 46th TD Cowen Health Care Conference; Kim Kelderman, interviewed by analyst Kyle Boucher, looks back on 50 years and lays out the growth plan, before the Merck KGaA deal was announced.
- History: started in Minnesota in 1976 with standards and controls for blood testing, then moved into proteins and antibodies, which gave broad scientific access to customers.
- Four growth verticals built on the core reagents: cell therapy, proteomic analysis, spatial biology and precision diagnostics; together they address a market of $27 billion growing at a mid-teens rate.
- Cell therapy: says Bio-Techne participates in 45% of all clinical studies; AI-generated proteins with higher specificity and heat stability; the coming Wilson Wolf acquisition (G-Rex bioreactor); organoids as a related opportunity.
- Proteomic analysis: new launches Leo (high-throughput western blot), CE mark for Ella in Europe, and an Ultra-Sensitive Cartridge for neuroscience.
- Precision diagnostics: kept Asuragen's ability to read hard-to-read genes; exited the low-margin Exosome lab business while keeping the gene-finding capability.
- Margins: gross margin "north of 70%" will continue; under normalized growth he expects to improve margins by "at least a hundred basis points annually"; divested lower-margin businesses; uses AI for productivity.
- Open to further M&A: room for "a fifth and a sixth growth verticals" using the same playbook.

### [Bio-Techne Q3 fiscal 2026 earnings call transcript](https://www.fool.com/earnings/call-transcripts/2026/05/06/bio-techne-tech-q3-2026-earnings-transcript/)

Executive talk · Kim Kelderman, President and Chief Executive Officer (with James Hippel, Chief Financial Officer) · 2026-05-06

- Q3 FY2026 (quarter to March 2026): revenue $311.4 million, down 2% organically; underlying organic growth was 2% after a 400 basis point headwind from two cell therapy customers with FDA Fast Track designation and a shifted OEM order.
- End markets: large pharma grew low double digits (sixth consecutive quarter of double-digit growth); emerging biotech fell high single digits despite funding up more than 90% and 50% in fiscal Q2 and Q3; U.S. academia returned to growth; China grew for the fourth consecutive quarter.
- Growth areas: Spatial Biology up mid-teens, COMET over 65% growth with a record backlog and its first install in China; GMP proteins up nearly 50% excluding the two Fast Track customers; Maurice up double digits; neurology assays on Ella at a 50% 3-year CAGR; Ella got CE-IVD marking.
- Brand alignment announced in April: 10 brands become 3, R&D Systems (including the former ProteinSimple instruments), Bio-Techne Spatial Biology and Bio-Techne Diagnostics.
- AI: designs novel, patentable proteins from five decades of proprietary data; COMET data used in the Providence Health and Microsoft GigaTIME framework.
- Profitability: adjusted operating margin 34.2% (up 310 basis points sequentially, down 70 year on year); adjusted EPS $0.53; cash $209.8 million, bank debt $200 million.
- Outlook: Q4 organic growth about flat; for fiscal 2027 Hippel said "we'd be disappointed if we didn't do at least mid-single-digit growth"; M&A "remains a top priority for capital allocation".

### [Bio-Techne Q2 fiscal 2026 earnings call transcript](https://www.fool.com/earnings/call-transcripts/2026/02/04/bio-techne-tech-q2-2026-earnings-call-transcript/)

Executive talk · Kim Kelderman, President and Chief Executive Officer (with James Hippel, Chief Financial Officer) · 2026-02-04

- Q2 FY2026 (quarter to December 2025): revenue $295.9 million, flat organic and reported; 4% organic growth excluding the two cell therapy customers with FDA Fast Track designation.
- The four growth verticals (cell therapy, proteomic analytical instrumentation, spatial biology, precision diagnostic tools) are 47% of total revenue, up from 32% in fiscal 2020, with an upper-teens CAGR over five years; the core grew at a mid-single-digit CAGR.
- End markets: large pharma up low double digits (fourth consecutive quarter); emerging biotech down mid-single digits; U.S. academia soft but stable; China up mid-single digits (third consecutive quarter of growth); APAC excluding China up almost 20%.
- Cell therapy revenue fell over 30% (GMP reagents down 50%) because of the two Fast Track customers; excluding them GMP reagents grew nearly 30%. Wilson Wolf grew 20% in the quarter.
- Innovation: ultra-sensitive Ella assays (2 to 5 times more sensitive), fluorescence detection added to the LEO western blot, Cultrex synthetic hydrogel for organoids (a business with a run rate of about $50 million in a $1.4 billion market); COMET bookings up nearly 40%.
- Profitability: adjusted operating margin 31.1%, up 100 basis points; adjusted EPS $0.46, up 10%; the company stayed on track for 100 basis points of margin expansion in fiscal 2026.
- M&A: Kelderman said the company had "not been able to pull a deal off yet"; targets include novel antibodies, broader cell therapy and proteomic analysis capabilities.

## Questions about Bio-Techne

### What does Bio-Techne do?

Bio-Techne makes life science reagents, instruments and services for research, diagnostics and bioprocessing, through two segments: Protein Sciences and Diagnostics and Spatial Biology. Its brands include R&D Systems, Bio-Techne Spatial Biology and Bio-Techne Diagnostics.

### What is Bio-Techne's revenue?

Net sales were $1,215.0 million in the fiscal year ended June 30, 2026, flat on FY2025's $1,219.6 million. In Q1 FY2027 net sales were $299.7 million, up 5%.

### How many employees does Bio-Techne have?

About 3,000 at June 30, 2026, with about 2,200 in the U.S. and about 800 outside.

### Who is acquiring Bio-Techne?

Merck KGaA, Darmstadt, Germany, agreed on June 25, 2026 to acquire Bio-Techne for $73.00 per share in cash. Shareholders approved the deal on September 23, 2026, and closing is expected by late 2026 or early 2027.

### Who leads Bio-Techne?

Kim Kelderman is President and CEO, James Hippel is CFO, William Geist leads Protein Sciences and Steve Crouse leads Diagnostics and Spatial Biology.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
